1. Home
  2. LPTX vs RSSS Comparison

LPTX vs RSSS Comparison

Compare LPTX & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • RSSS
  • Stock Information
  • Founded
  • LPTX 2011
  • RSSS 2006
  • Country
  • LPTX United States
  • RSSS United States
  • Employees
  • LPTX N/A
  • RSSS N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • RSSS Business Services
  • Sector
  • LPTX Health Care
  • RSSS Consumer Discretionary
  • Exchange
  • LPTX Nasdaq
  • RSSS Nasdaq
  • Market Cap
  • LPTX 91.8M
  • RSSS 86.4M
  • IPO Year
  • LPTX N/A
  • RSSS N/A
  • Fundamental
  • Price
  • LPTX $2.33
  • RSSS $2.78
  • Analyst Decision
  • LPTX Strong Buy
  • RSSS Strong Buy
  • Analyst Count
  • LPTX 5
  • RSSS 1
  • Target Price
  • LPTX $10.40
  • RSSS $6.00
  • AVG Volume (30 Days)
  • LPTX 116.7K
  • RSSS 39.5K
  • Earning Date
  • LPTX 11-11-2024
  • RSSS 11-07-2024
  • Dividend Yield
  • LPTX N/A
  • RSSS N/A
  • EPS Growth
  • LPTX N/A
  • RSSS N/A
  • EPS
  • LPTX N/A
  • RSSS N/A
  • Revenue
  • LPTX N/A
  • RSSS $44,623,899.00
  • Revenue This Year
  • LPTX N/A
  • RSSS $13.76
  • Revenue Next Year
  • LPTX N/A
  • RSSS $9.92
  • P/E Ratio
  • LPTX N/A
  • RSSS N/A
  • Revenue Growth
  • LPTX N/A
  • RSSS 18.35
  • 52 Week Low
  • LPTX $1.31
  • RSSS $2.21
  • 52 Week High
  • LPTX $5.00
  • RSSS $3.50
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 40.85
  • RSSS 57.39
  • Support Level
  • LPTX $2.20
  • RSSS $2.69
  • Resistance Level
  • LPTX $2.45
  • RSSS $2.80
  • Average True Range (ATR)
  • LPTX 0.16
  • RSSS 0.08
  • MACD
  • LPTX -0.01
  • RSSS 0.01
  • Stochastic Oscillator
  • LPTX 21.14
  • RSSS 92.00

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides a cloud-based SaaS research intelligence platform consisting of proprietary software and Internet-based interfaces. Its platform also allows customers to find and download digital versions of STM articles. Platforms and Transactions are packaged as a single solution that enables life science and other research-intensive organizations to speed up research and development activities. The company platform allows customers to initiate orders, manage transactions, automate authentication, obtain reports, and connect seamlessly to corporate intranets.

Share on Social Networks: